Form 4: Cognition Therapeutics CFO Vests Performance Stock Units

Cognition Therapeutics' Chief Financial Officer, John Brendan Doyle, reported the vesting of performance stock units and subsequent tax-related share disposition.

Summary

• John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), reported transactions related to his beneficial ownership of company stock.
• On December 18, 2025, 30,000 shares of Common Stock were acquired by Mr. Doyle upon the vesting of performance stock units (PSUs).
• These PSUs were initially granted on February 14, 2024, and the reported transaction represents the vesting of the remaining 50% of the total shares subject to these PSUs.
• Concurrently, 9,360 shares of Common Stock were disposed of at a price of $1.50 per share to cover tax withholding obligations associated with the PSU vesting.
• Following these transactions, Mr. Doyle directly beneficially owns 445,990 shares of Cognition Therapeutics Inc. Common Stock.

Sentiment

Score: 6

Explanation: The vesting of PSUs is a positive indicator of performance goal achievement, offset slightly by the routine disposition of shares for tax purposes. It reflects standard executive compensation practices and does not introduce significant new information.

Positives

• The vesting of performance stock units indicates the achievement of certain performance goals, which is generally a positive sign for the company's operational execution.
• The Chief Financial Officer's continued significant direct beneficial ownership of 445,990 shares aligns his interests with those of the company's shareholders.

Negatives

• A disposition of 9,360 shares occurred, reducing the Chief Financial Officer's direct holdings, although this was for tax withholding purposes.

Future Outlook

NA

Industry Context

This filing details a routine executive compensation event and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The vesting of PSUs suggests management is meeting performance targets, which could be viewed positively. The CFO's continued significant ownership aligns interests with shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance stock units and a subsequent tax-related share disposition. It does not present new information that would fundamentally alter the investment thesis for Cognition Therapeutics. The CFO's continued substantial direct ownership is a positive, aligning management interests with shareholders. Investors should 'hold' and focus on the company's operational performance and future financial reports for investment decisions.

Keywords

Cognition Therapeutics, CGTX, Form 4, Insider Transaction, John Brendan Doyle, CFO, Performance Stock Units, PSU Vesting, Stock Ownership, Executive Compensation